New study reveals crucial protein interactions in Duchenne Muscular Dystrophy, opening doors to more precise and effective ...

Exciting news in the biotech industry as positive phase 2 results for sevasemten in BMD drive long-term investment potential ...

Study results provide root explanations for how dystrophin functions on a molecular level, providing base-level insights into ...

On their family farm in rural Illinois, the Flessner boys have free range. But early on, something was holding older brother ...

A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for ...

From imaging innovations to new treatment approvals, 2024 brought advancements in Duchenne muscular dystrophy care and ...

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Duchenne Muscular Dystrophy.

The newly approved medicines in 2024 from Massachusetts companies range from a schizophrenia drug to a gene therapy for ...

An advanced centre for treating muscular dystrophy will soon be established at Chacha Nehru Children’s Hospital. The decision ...

Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) inpatients aged 4 years and older Follows recent approval from China’s National Medical ...

Patients with Duchenne muscular dystrophy now have new hope with gene ... and now gene replacement therapy – have changed the treatment landscape. For the Flessners, it’s a double blessing.